Estrogen Replacement Therapy (ERT) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2022 - 2027

Report Code: HCR 0631 Report Format: PDF + Excel

Estrogen Replacement Therapy (ERT) Market Overview

Estrogen Replacement Therapy (ERT) Market size is estimated to reach $13.2 billion by 2027, growing at a CAGR of 5.7% during the forecast period 2022-2027. Estrogen replacement therapy (ERT) is a kind of therapy with estrogen hormones most typically utilized to treat the symptoms of menopause. It decreases or halts the short-term alterations of menopause like hot flashes, disrupted sleep, and vaginal dryness. Hormone replacement therapies (HRTs) are treatment methods for substituting and/or restoring hormones in the human body, which are at insufficient levels than those needed for the typical physiology of the human body. The most important usage of HRT is in the treatment of symptom relief of menopause for which ERT may be applied. Prader-Willi syndrome is a genetic ailment that influences numerous portions of the body and its development. It brings about mental and behavioral issues. Estrogen replacement therapies are being utilized more and more for the treatment of Prader-Willi syndrome. There has been the establishment of new drug delivery systems (NDDSs) like vaginal estrogen medications and transdermal estrogen patches. progesterone and estrogen are both hormones that are frequently taken together.
The expanding demand for hormone replacement therapies like Estrogen Replacement Therapy (ERT) is set to drive the Estrogen Replacement Therapy (ERT) Market. The increasing predominance of Prader-Willi syndrome is set to propel the growth of the Estrogen Replacement Therapy (ERT) Market during the forecast period 2022-2027. This represents the Estrogen Replacement Therapy (ERT) Industry Outlook.

Report Coverage

The report: Estrogen Replacement Therapy (ERT) Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Estrogen Replacement Therapy (ERT) Market.

By Dosage Form: Tablets, Patches, Gels, Implants, Injections, Suppositories.

By Route Of Administration: Oral, Subcutaneous, Topical.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Estrogen Replacement Therapy (ERT) Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the existence of the U.S. which occupies the biggest global market share for hormone replacement therapies like Estrogen Replacement Therapy in the North American region.
  • Estrogen Replacement Therapy (ERT) Market growth is being driven by the surging awareness regarding menopausal symptoms requiring the application of hormone replacement therapies like estrogen replacement therapy and its treatment options. However, the post-treatment hazard of cervical cancer and coronary disease is one of the major factors hampering the growth of the Estrogen Replacement Therapy (ERT) Market. 
  • Estrogen Replacement Therapy (ERT) Market Detailed Analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Estrogen Replacement Therapy (ERT) Market report.

    Estrogen Replacement Therapy (ERT) Market: Market Share (%) by Region, 2021


    For more details on this report - Request for Sample 

Estrogen Replacement Therapy (ERT) Market Segment Analysis – By Dosage Form:

The Estrogen Replacement Therapy (ERT) Market based on dosage form can be further segmented into Tablets, Patches, Gels, Implants, Injections, and Suppositories. The Tablets Segment held the largest market share in 2021. This growth is owing to the surging acceptance of the tablet form for hormone replacement therapies and a boost In the demand for progressive dosage forms for progesterone and estrogen hormonal therapies. Estradiol is a female sex hormone termed estrogen. The proliferating demand for drug delivery systems is further propelling the growth of the Tablets segment.
Furthermore, the Injections segment is estimated to grow with the fastest CAGR of 6.7% during the forecast period 2022-2027 owing to the heightening demand for injections for women encountering vaginal dryness and the increasing acceptance of estradiol injections in treating symptoms of menopause.

Estrogen Replacement Therapy (ERT) Market Segment Analysis – By Route Of Administration:

The Estrogen Replacement Therapy (ERT) Market based on the route of administration can be further segmented into Oral, Subcutaneous, and Topical. The Oral Segment held the largest market share in 2021. This growth is owing to the effortless accessibility of oral estrogens for hormone replacement therapies and the increasing demand for decreasing menopausal symptoms in women. A low-dose estrogen Oral Contraceptive is an alternative at the time of the menopausal transition unless contraindicated for perimenopausal (40–50 years) women who look for alleviation of menopausal symptoms. The proliferating inclination of patients worldwide towards the oral route of administration in conjunction with the heightening application of hormone replacement therapies is further propelling the growth of this segment.
Furthermore, the Subcutaneous segment is estimated to grow with the fastest CAGR of 6.2% during the forecast period 2022-2027 owing to the extensive application of novel drug delivery stems including subcutaneous products for long term hormone replacement therapies and the proliferating significance of subcutaneous route of administration for progesterone and estrogen hormonal treatments.

Estrogen Replacement Therapy (ERT) Market Segment Analysis – By Geography:

The Estrogen Replacement Therapy (ERT) Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America (Estrogen Replacement Therapy (ERT) Market) held the largest share with 37% of the overall market in 2021. The growth of this region is owing to the surging population of elderly women in the North American region. Hormone replacement therapies like estrogen replacement therapy are extensively utilized for the relief of menopausal symptoms. The soaring demand for progressive drug delivery systems is further propelling the growth of the Estrogen Replacement Therapy (ERT) Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like heightened financing by key players to develop progressive hormone replacement therapies including estrogen replacement therapy in the Asia-Pacific region. The extensive acceptance of progressive dosage forms for progesterone and estrogen is further fuelling the progress of the Estrogen Replacement Therapy (ERT) Market in the Asia-Pacific region.

Estrogen Replacement Therapy (ERT) Market - Drivers

Surging Applications Of Hormone Replacement Therapies (HRT) Are Projected To Drive The Growth Of Estrogen Replacement Therapy (ERT) Market:

As per data maintained by the Centers For Disease Control and Prevention (CDC), among postmenopausal women who had ever utilized hormone replacement therapies (HRTs),

  1. 17% began this therapy prior to experiencing natural or surgical menopause
  2. 48% began this therapy within a year subsequent to menopause
  3. 10% began 2-4 years subsequent to menopause
  4. 25% began 5 or more years subsequent to menopause

Hormone replacement therapies are medicines that include female hormones. The medicine is consumed to substitute the estrogen that the body halts preparing at the time of menopause. Hormone therapy is most frequently utilized to treat typical menopausal symptoms, inclusive of hot flashes and vaginal discomfort. Hormone replacement therapies have been confirmed to avert bone loss and decrease fracture in postmenopausal women. For excellent outcomes, hormone therapy should be custom-made for every person and reassessed every so frequently to be certain that the advantages still cancel out the hazards. The surging applications of Hormone Replacement Therapies (HRTs) are therefore fuelling the growth of the Estrogen Replacement Therapy (ERT) Market during the forecast period 2022-2027.

Proliferating Applications Of Drug Delivery Systems Are Expected To Boost The Demand For Estrogen Replacement Therapy (ERT):

Technological innovations in drug delivery systems are fuelling the growth of the Estrogen Replacement Therapy (ERT) Market. Certain progressive drug delivery systems include vaginal estrogen patches, transdermal estrogen patches, and low-dose estrogen replacement therapy. Nearly all brand-name estradiol patches will arrive in 100mcg doses which lasts for three to four days. The average weekly dosage for estrogen HRT is 400mcg, which equalizes to four patches per week, two patches at a time for 3-4 days each. For those interested in beginning with low-dose estrogen, the transdermal patches arrive in varying strengths. Numerous transdermal therapeutic systems (TTS) discharging estrogens, progestogens, and androgens from patches fastened to the skin are presently in clinical application. For women, transdermal systems have been established for hormonal replacement therapy (HRT) and currently for contraception. Hormone replacement therapies with patches discharging only estradiol (E2) need to be augmented with a progestogen to safeguard the endometrium. The proliferating applications of drug delivery systems are therefore driving the growth of the Estrogen Replacement Therapy (ERT) Market during the forecast period 2022-2027.

Estrogen Replacement Therapy (ERT) Market – Challenges

Disadvantages Of Estrogen Replacement Therapy Are Hampering The Growth Of The Estrogen Replacement Therapy (ERT) Market:

An unrecognized count of younger women have ovarian deficiencies and have halted menstruating owing to surplus dieting or exercise. Presently, however, only 4 million to 5 million such women are accepting estrogen replacement therapy or ERT. When administered with estrogen-only hormone replacement therapies, the side effects of the hormone estrogen experienced are bloating, tenderness or swelling in body parts such as the breasts, leg cramps, headache, stomach issues such as indigestion, and vaginal bleeding. When a woman enters menopause and starts to experience adverse impacts of this condition, there is an apprehension about receiving the estrogen replacement therapy owing to the risks that may be involved. As aggravating as those hot flashes may be, numerous women opt to manage them instead of going in for therapy with the possible raised chances of hazards of heart attack, blood clots, breast cancer, stroke, or uterine cancer. These issues are thus hampering the growth of the Estrogen Replacement Therapy (ERT) Market.

Estrogen Replacement Therapy (ERT) Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Estrogen Replacement Therapy (ERT) Market. Key companies in this market are:

  1. AbbVie Inc.
  2. Bayer AG
  3. Hisamitsu Pharmaceutical Co., Inc.
  4. Novartis AG
  5. Novo Nordisk A/S
  6. Orion Pharma AB
  7. Meda Pharmaceuticals
  8. Pfizer Inc
  9. Teva Pharmaceutical Industries Ltd.
  10. TherapeuticsMD Inc,

Recent Developments

  • In January 2022, Novo Nordisk India has introduced the planet’s first and only “peptide in a pill”, oral semaglutide, a gamechanger in diabetes handling. Semaglutide, a GLP-1 receptor analog (GLP-1 RA) – one of the drug classes to treat diabetes, till now was accessible only in the form of injections. This is the earliest time a GLP-1 RA has been established in an oral formulation.
  • In April 2021, TherapeuticsMD, Inc, and Theramex, declared that BIJUVE® has accepted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) for application in the U.K. and from the Federal Agency for Medicines and Health Products (FAMHP) for application in Belgium under BIJUVA®.  A “decentralized procedure” (DCP) for the regulatory authorization of BIJUVA® in numerous European countries was finished in February. Following this, every country engages in a nationwide procedure that is inclusive of authorizations for labeling and additional country particular needs.
  • In February 2020, Novo Nordisk declared that ESPEROCT® [antihemophilic factor (recombinant), glycopegylated-exei] is presently accessible in the U.S. for the treatment of mature grown-ups and children with hemophilia A. ESPEROCT® is a recombinant extended half-life factor VIII replacement therapy utilized to avert or decrease the count of bleeding episodes, to treat and curb bleeding, and to handle bleeding at the time of surgery in people with hemophilia A. Hemophilia A is an incessant, inherited bleeding ailment, which influences about 20,000 people in the U.S.

Related Reports-

Report Code: HCR 0222
Report Code: HCR 0395
Report Code: CMR 1001
For more Lifesciences and Healthcare Market reports, please click here

1. Estrogen Replacement Therapy (ERT) Market Overview
    1.1 Definitions and Scope
2. Estrogen Replacement Therapy (ERT) Market - Executive Summary
3. Estrogen Replacement Therapy (ERT) Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Estrogen Replacement Therapy (ERT) Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Estrogen Replacement Therapy (ERT) Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Estrogen Replacement Therapy (ERT) Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Estrogen Replacement Therapy (ERT) Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Estrogen Replacement Therapy (ERT) Market - By Dosage Form (Market Size –$Million/$Billion) 
    8.1 Tablets
    8.2 Patches
    8.3 Gels
    8.4 Implants
    8.5 Injections
    8.6 Suppositories
9. Estrogen Replacement Therapy (ERT) Market - By Route Of Administration (Market Size –$Million/$Billion) 
    9.1 Oral
    9.2 Subcutaneous
    9.3 Topical
10. Estrogen Replacement Therapy (ERT) Market - By Geography (Market Size -$Million/Billion)
    10.1 North America
        10.1.1 U.S
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
        10.5.1 Middle East
        10.5.2 Africa
11. Estrogen Replacement Therapy (ERT) Market - Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs and partnerships
12. Estrogen Replacement Therapy (ERT) Market – Industry Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key Companies
        12.1.3 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Estrogen Replacement Therapy (ERT) Market – Key Company List by Country Premium (Premium)
14. Estrogen Replacement Therapy (ERT) Market - Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"